In our last review of Bristol-Myers Squibb (BMY) on March 9 after a quantitative downgrade from TheStreet's Quant Ratings service, we wrote that, "The downgrade to hold by our quantitative service does not help our cause. At current levels BMY is sort-of in no man's land - not bullish and not bearish. Traders who are flat should wait for a close above $68 to go long, and traders who are still long and can risk a wider stop could hold."
More from Stocks
We are all looking for the secret sauce that will help us guide our way to prosperity, but here's where the best tools for investing are.
Here's a play in this meme name as the SEC takes a bit role in trading subplot.
The mixed action on Monday is not a negative -- and here's why SPACs are getting interesting again.